重组改构人肿瘤坏死因子联合顺铂治疗肺癌恶性胸腔积液的效果  

The therapeutic effect of rmh-TNF combined cisplatin in treating lung cancer with malignant pleural effusion

作　　者：胡涛[1] 陈晓林[1] 黄玉民[1] 陶玉坚[1] 

机构地区：[1]江苏省扬州市第一人民医院呼吸科,江苏扬州225012

出　　处：《中国当代医药》2016年第2期47-49,共3页China Modern Medicine

摘　　要：目的观察重组改构人肿瘤坏死因子（rmh-TNF）联合顺铂治疗肺癌恶性胸腔积液的效果及不良反应。方法选取2013年1月-2014年12月在我科住院治疗的60例肺癌恶性胸腔积液患者,将其随机分为治疗组和对照组各30例。治疗组胸腔局部注入rmh-TNF 2×106U联合顺铂30 mg,每周1次,对照组胸腔局部注入单药顺铂30 mg,每周1次。观察两组的疗效及不良反应。结果第二次治疗后,治疗组完全缓解（CR）14例,部分缓解（PR）12例,无变化（NC）4例,总有效率为86.7%;对照组CR 8例,PR 8例,NC 14例,总有效率为53.3%,两组比较差异有统计学意义（P〈0.01）。常见不良反应为胸痛、胃肠道反应（恶性、呕吐）及发热,治疗组胸痛、胃肠道反应（恶性、呕吐）发生率分别为43.3%（13/30）、23.3%（7/30）。对照组发生率分别为33.3%（10/30）、30.0%（9/30）,两组比较差异无统计学意义（P〉0.05）;治疗组发热发生率为46.7%（14/30）,对照组发生率为16.7%（5/30）,两组比较差异有统计学意义（P〈0.05）。结论 rmh-TNF联合顺铂局部胸腔注射治疗肺癌恶性胸腔积液效果可靠,不良反应轻微。Objective To observe the therapeutic effect and adverse reactions of recombinant mutant human tumor necrosis factor（rmh-TNF） combined cisplatin in the treatment of lung cancer with malignant pleural effusion. Methods Sixty patients of lung cancer with malignant pleural effusion from January 2013 to December 2014 in our hospital were chosen and randomly divided into treatment group and control group.Treatment group were injected intrapleurally with rmh-TNF combined cisplatin at a dose of 2×106U and 30 mg after complete drainage,once a week;control group were injected intrapleurally with cisplatin at a dose of 30 mg,once a week,the effect and adverse reactions were observed.Results Among the treatment group,14 patients were complete response（CR）,12 patients were partial response（PR） and4 patients were no change（NC）,the overall response rate was 86.7%,among the control group,8 patients were CR,8 patients were PR and 14 patients were NC,the overall response rate was 53.3%,the difference was statistically significant（P〈0.01）.Common adverse reactions were common chest pain,the incidence of gastrointestinal reaction（malignant,vomiting） in treatment group was 43.3%（13/30）,23.3%（7/30） respectively, and was 33.3%（10/30）,30.0%（9/30） in control group,the difference was no statistically significant（P〈0.05）.The incidence of fever in treatment group was 46.7%（14/30）,and was 16.7%（5/30） in control group,the difference was statistically significant（P〈0.05）. Conclusion The rmhTNF combined cisplatin is effective in the treatment of lung cancer with malignant pleural effusion,and with slide adverse reactions.

关 键 词：肺癌 恶性胸腔积液 rmh-TNF 顺铂 胸腔注射 

分 类 号：R730.5[医药卫生—肿瘤]